Bendamustine injection - Jiangsu Simcere Pharmaceutical

Drug Profile

Bendamustine injection - Jiangsu Simcere Pharmaceutical

Alternative Names: Bendamustine hydrochloride injection - Simcere

Latest Information Update: 14 Aug 2015

Price : $50

At a glance

  • Originator Jiangsu Simcere Pharmaceutical; Simcere Pharmaceutical Group
  • Developer Jiangsu Simcere Pharmaceutical
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration B cell lymphoma; Chronic lymphocytic leukaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Aug 2013 Simcere completes a phase II trial in Chronic lymphocytic leukaemia (treatment naive) in China (NCT01109264)
  • 25 Apr 2012 Phase-III clinical trials in Chronic lymphocytic leukaemia in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top